The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10588 malaria professionals are enjoying the free benefits of MalariaWorld today

sulfadoxine-pyrimethamine

Two-Year Scale-Up of Seasonal Malaria Chemoprevention Reduced Malaria Morbidity among Children in the Health District of Koutiala, Mali

September 16, 2020 - 13:07 -- Open Access
Author(s): 
Maiga H, Gaudart J, Djimde AA, et al.
Reference: 
Int J Environ Res Public Health. 2020 Sep 11;17(18):E6639

Previous controlled studies demonstrated seasonal malaria chemoprevention (SMC) reduces malaria morbidity by >80% in children aged 3-59 months. Here, we assessed malaria morbidity after large-scale SMC implementation during a pilot campaign in the health district of Koutiala, Mali.

Sub-optimal Intermittent Preventive Treatment in pregnancy (IPTp) is associated with an increased risk of submicroscopic P. falciparum infection in pregnant women: a prospective cohort study in Benin

September 10, 2020 - 08:51 -- Open Access
Author(s): 
Hounkonnou CPA, Ndam NT, Fievet N, Accrombessi M, Yovo E, Mama A, Sossou D, Vianou B, Massougbodji A, Briand V, Cot M, Cottrell G
Reference: 
Clin Infect Dis. 2020 Sep 9:ciaa1355

Harmful maternal and neonatal health outcomes result from malaria in pregnancy, the prevention of which primarily relies on intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP). WHO recommends IPTp-SP in sub-Saharan Africa, but implementation is highly heterogeneous and often sub-optimal in terms of the number of doses and their timing. In this study, we assessed the impact of this heterogeneity on malaria in pregnancy, mainly with respect to submicroscopic Plasmodium falciparum infections.

Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial

August 11, 2020 - 07:39 -- Open Access
Author(s): 
Kakuru A, Jagannathan P, Dorsey G, et al.
Reference: 
BMC Med. 2020 Aug 10;18(1):207

Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (SP), the current standard of care, but its impact on the incidence of malaria during infancy is unknown.

NOT Open Access | Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi

July 27, 2020 - 12:29 -- NOT Open Access
Author(s): 
Taylor SM, Levitt B, Freedman B, Madanitsa M, Thwai KL, Kalilani-Phiri L, Khairallah C, Mwapasa V, Ter Kuile FO, Meshnick SR
Reference: 
J Infect Dis. 2020 Jul 23; 222(4):661-669

Sulfadoxine-pyrimethamine (SP) is used as intermittent preventive therapy in pregnancy (IPTp) for malaria in sub-Saharan Africa. The resistance marker dhps A581G has been associated with reduced IPTp-SP efficacy and enhanced morbidity in SP recipients.

Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania

July 26, 2020 - 13:34 -- Open Access
Author(s): 
Bwire GM, Mikomangwa WP, Kilonzi M
Reference: 
BMC Infect Dis. 2020 Jul 22;20(1):530

Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations compromise the effectiveness of sulfadoxine-pyrimethamine (SP) for treatment of uncomplicated malaria, and are likely to impair the efficiency of intermittent preventive treatment during pregnancy (IPTp). This study was conducted to determine the level of Pfdhfr-Pfdhps mutations, a decade since SP was limited for IPTp use in pregnant women in Tanzania.

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017

July 15, 2020 - 15:13 -- Open Access
Author(s): 
Kasama Rakmark, Ghulam R. Awab, Jureeporn Duanguppama, Usa Boonyuen, Arjen M. Dondorp and Mallika Imwong
Reference: 
Malaria Journal 2020 19:251, 14 July 2020

Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has been first-line treatment for uncomplicated falciparum malaria until 2016. Although SP has been the recommended treatment for falciparum and not vivax malaria, exposure of the P. vivax parasite population to SP might still have been quite extensive because of community based management of malaria. The change in the P. vivax antifolate resistance markers between 2007 and 2017 were investigated.

Defining the combined benefit of intermittent preventive malaria treatment in pregnancy

July 8, 2020 - 15:27 -- Open Access
Author(s): 
Salman S, Davis TME, Moore B
Reference: 
Lancet Glob Health. 2020 Jul;8(7):e871-e872

WHO  has  included  intermittent  preventive  treatment  in  pregnancy  (IPTp)  with  sulfadoxine-pyrimethamine  as  an  important  malaria  intervention  since  2012.1  Although  other candidate therapies remain under investigation and despite  waning  sulfadoxine-pyrimethamine  antimalarial  efficacy  due  to  increasing  parasite  resistance,  IPTp  with  sulfadoxine-pyrimethamine  remains  a  key  component  of   the   management   of   pregnant   women   in   malaria-endemic areas. In areas of high-grade parasite resistance, the   use   of   IPTp   with   sulfadoxine-pyrimethamine   is   associated with improved birth weight, suggesting that there are benefits of beyond antimalarial efficacy.

Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis

July 8, 2020 - 15:25 -- Open Access
Author(s): 
Roh ME, Kuile FOT, Rerolle F, Glymour MM, Shiboski S, Gosling R, Gutman J, Kakuru A, Desai M, Kajubi R, L'Ianziva A, Kamya MR, Dorsey G, Chico RM
Reference: 
Lancet Glob Health. 2020 Jul;8(7):e942-e953

Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was superior at preventing malaria infection, but not at improving birthweight. We aimed to assess whether sulfadoxine-pyrimethamine shows greater non-malarial benefits for birth outcomes than does dihydroartemisinin-piperaquine, and whether dihydroartemisinin-piperaquine shows greater antimalarial benefits for birth outcomes than does sulfadoxine-pyrimethamine.

Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania

April 20, 2020 - 09:51 -- Open Access
Author(s): 
Wigilya P. Mikomangwa, Omary Minzi, Ritah Mutagonda, Vito Baraka, Eulambius M. Mlugu, Eleni Aklillu and Appolinary A. R. Kamuhabwa
Reference: 
Malaria Journal 2020 19:160, 19 April 2020

Malaria in pregnancy increases the risk of deleterious maternal and birth outcomes. The use of ≥ 3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (IPTp-SP) is recommended for preventing the consequences of malaria during pregnancy. This study assessed the effect of IPTp-SP for prevention of malaria during pregnancy in low transmission settings.

Correlates of uptake of optimal doses of sulfadoxine-pyrimethamine for prevention of malaria during pregnancy in East-Central Uganda

April 18, 2020 - 13:55 -- Open Access
Author(s): 
Mbonye K. Martin, Kirwana B. Venantius, Ndugga Patricia, Kikaire Bernard, Baleeta Keith, Kabagenyi Allen, Asiimwe Godfrey, Twesigye Rogers, Kadengye T. Damazo and Byonanebye M. Dathan
Reference: 
Malaria Journal 2020 19:153, 15 April 2020

In 2012, the World Health Organization recommended that pregnant women in malaria-endemic countries complete at least three (optimal) doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) to prevent malaria and related adverse events during pregnancy. Uganda adopted this recommendation, but uptake remains low in East-Central and information to explain this low uptake remains scanty. This analysis determined correlates of uptake of optimal doses of IPTp-SP in East-Central Uganda.

Pages

Subscribe to RSS - sulfadoxine-pyrimethamine